Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - EQ 10GM BASE/...DOSAGE - INJECTABLE;INJECTION - EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50547
DOSAGE - INJECTABLE;INJECTION - EQ 1GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50547
DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50547
DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE...DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50547
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
75
PharmaCompass offers a list of Cefotaxime API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Cefotaxime manufacturer or Cefotaxime supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cefotaxime manufacturer or Cefotaxime supplier.
A Cefotaxime, Sodium Salt manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cefotaxime, Sodium Salt, including repackagers and relabelers. The FDA regulates Cefotaxime, Sodium Salt manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cefotaxime, Sodium Salt API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cefotaxime, Sodium Salt manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Cefotaxime, Sodium Salt supplier is an individual or a company that provides Cefotaxime, Sodium Salt active pharmaceutical ingredient (API) or Cefotaxime, Sodium Salt finished formulations upon request. The Cefotaxime, Sodium Salt suppliers may include Cefotaxime, Sodium Salt API manufacturers, exporters, distributors and traders.
click here to find a list of Cefotaxime, Sodium Salt suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Cefotaxime, Sodium Salt DMF (Drug Master File) is a document detailing the whole manufacturing process of Cefotaxime, Sodium Salt active pharmaceutical ingredient (API) in detail. Different forms of Cefotaxime, Sodium Salt DMFs exist exist since differing nations have different regulations, such as Cefotaxime, Sodium Salt USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cefotaxime, Sodium Salt DMF submitted to regulatory agencies in the US is known as a USDMF. Cefotaxime, Sodium Salt USDMF includes data on Cefotaxime, Sodium Salt's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cefotaxime, Sodium Salt USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cefotaxime, Sodium Salt suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cefotaxime, Sodium Salt Drug Master File in Japan (Cefotaxime, Sodium Salt JDMF) empowers Cefotaxime, Sodium Salt API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cefotaxime, Sodium Salt JDMF during the approval evaluation for pharmaceutical products. At the time of Cefotaxime, Sodium Salt JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cefotaxime, Sodium Salt suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cefotaxime, Sodium Salt Drug Master File in Korea (Cefotaxime, Sodium Salt KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cefotaxime, Sodium Salt. The MFDS reviews the Cefotaxime, Sodium Salt KDMF as part of the drug registration process and uses the information provided in the Cefotaxime, Sodium Salt KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cefotaxime, Sodium Salt KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cefotaxime, Sodium Salt API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cefotaxime, Sodium Salt suppliers with KDMF on PharmaCompass.
A Cefotaxime, Sodium Salt CEP of the European Pharmacopoeia monograph is often referred to as a Cefotaxime, Sodium Salt Certificate of Suitability (COS). The purpose of a Cefotaxime, Sodium Salt CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cefotaxime, Sodium Salt EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cefotaxime, Sodium Salt to their clients by showing that a Cefotaxime, Sodium Salt CEP has been issued for it. The manufacturer submits a Cefotaxime, Sodium Salt CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cefotaxime, Sodium Salt CEP holder for the record. Additionally, the data presented in the Cefotaxime, Sodium Salt CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cefotaxime, Sodium Salt DMF.
A Cefotaxime, Sodium Salt CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cefotaxime, Sodium Salt CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cefotaxime, Sodium Salt suppliers with CEP (COS) on PharmaCompass.
A Cefotaxime, Sodium Salt written confirmation (Cefotaxime, Sodium Salt WC) is an official document issued by a regulatory agency to a Cefotaxime, Sodium Salt manufacturer, verifying that the manufacturing facility of a Cefotaxime, Sodium Salt active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cefotaxime, Sodium Salt APIs or Cefotaxime, Sodium Salt finished pharmaceutical products to another nation, regulatory agencies frequently require a Cefotaxime, Sodium Salt WC (written confirmation) as part of the regulatory process.
click here to find a list of Cefotaxime, Sodium Salt suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cefotaxime, Sodium Salt as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cefotaxime, Sodium Salt API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cefotaxime, Sodium Salt as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cefotaxime, Sodium Salt and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cefotaxime, Sodium Salt NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cefotaxime, Sodium Salt suppliers with NDC on PharmaCompass.
Cefotaxime, Sodium Salt Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cefotaxime, Sodium Salt GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Cefotaxime, Sodium Salt GMP manufacturer or Cefotaxime, Sodium Salt GMP API supplier for your needs.
A Cefotaxime, Sodium Salt CoA (Certificate of Analysis) is a formal document that attests to Cefotaxime, Sodium Salt's compliance with Cefotaxime, Sodium Salt specifications and serves as a tool for batch-level quality control.
Cefotaxime, Sodium Salt CoA mostly includes findings from lab analyses of a specific batch. For each Cefotaxime, Sodium Salt CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cefotaxime, Sodium Salt may be tested according to a variety of international standards, such as European Pharmacopoeia (Cefotaxime, Sodium Salt EP), Cefotaxime, Sodium Salt JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cefotaxime, Sodium Salt USP).
